ARTICLE | Emerging Company Profile
CD38 hat trick
Why Tusk believes its anti-CD38 mAb could be best in class
December 15, 2017 9:58 PM UTC
Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates effector T cells.
The CD38 space initially gained prominence based on the speedy development and commercial success of Genmab A/S and Johnson & Johnson’s Darzalex daratumumab in multiple myeloma (MM). ...
BCIQ Company Profiles
BCIQ Target Profiles